33,531 Shares in Royalty Pharma plc (NASDAQ:RPRX) Acquired by 111 Capital

111 Capital acquired a new stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,531 shares of the biopharmaceutical company's stock, valued at approximately $855,000.

A number of other hedge funds have also made changes to their positions in the stock. Nissay Asset Management Corp Japan ADV increased its holdings in shares of Royalty Pharma by 0.7% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock valued at $1,238,000 after acquiring an additional 349 shares during the last quarter. Keene & Associates Inc. grew its holdings in Royalty Pharma by 1.9% in the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock valued at $495,000 after buying an additional 370 shares during the last quarter. National Bank of Canada FI grew its holdings in Royalty Pharma by 21.8% in the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 371 shares during the last quarter. Blue Trust Inc. grew its holdings in Royalty Pharma by 31.3% in the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 376 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC grew its holdings in Royalty Pharma by 1.1% in the 4th quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock valued at $890,000 after buying an additional 380 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Stock Performance

Shares of RPRX stock traded up $0.38 during mid-day trading on Monday, reaching $33.26. The stock had a trading volume of 4,168,567 shares, compared to its average volume of 3,528,692. The firm's 50 day simple moving average is $32.34 and its 200 day simple moving average is $30.50. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.32. The firm has a market cap of $18.70 billion, a PE ratio of 22.94, a P/E/G ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. The company had revenue of $839.00 million during the quarter, compared to the consensus estimate of $724.69 million. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $0.22 per share. The ex-dividend date is Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.65%. Royalty Pharma's dividend payout ratio (DPR) is presently 47.57%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on RPRX shares. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Morgan Stanley started coverage on Royalty Pharma in a report on Friday, May 16th. They issued an "overweight" rating and a $51.00 target price on the stock. Finally, Wall Street Zen lowered Royalty Pharma from a "buy" rating to a "hold" rating in a report on Tuesday, May 20th. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.